Drugs / Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)
Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06564116 | Mar 2023 → Mar 2024 | hepatitis E virus infection | Xiamen Innovax Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thiomersal-free Recombinant Hepatitis E Vaccine (Escherichia Coli) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06564116 ↗ |
| Modality | Vaccine | “Thiomersal-free hepatitis E vaccine” NCT06564116 ↗ |
| Route | Intramuscular | “Participants would receive 3 doses of thiomersal-free hepatitis E vaccine intramuscularly at month 0, 1 and 6.” NCT06564116 ↗ |